Quest PharmaTech Inc.
Quest PharmaTech Inc. (QPTFF) Stock Overview
Explore Quest PharmaTech Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
13M
P/E Ratio
-5.13
EPS (TTM)
$-0.01
ROE
-0.08%
QPTFF Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Quest PharmaTech Inc. (QPTFF) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of F, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $0.03.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -5.13 and a market capitalization of 13M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
Quest PharmaTech Inc., a pharmaceutical company, develops antibody based immunotherapeutic products for cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, an anti-CA-125 antibody, which has completed Phase II clinical trial for the treatment of ovarian cancer. In addition, it develops, manufactures, and commercializes immunotherapy products for pancreatic cancer. Further, the company develops products by using proprietary transdermal delivery technologies for dermatology and wound healing applications; skin penetrating active molecules for cosmetic and pharmaceutical use; and combinatorial immunotherapeutic products for the treatment cancer by using monoclonal antibodies of the immunoglobulin of G and E class. Quest PharmaTech Inc. is headquartered in Edmonton, Canada.
Ragupathy Madiyalakan
8123 Roper Road NW, Edmonton, AB
2018